Geode Capital Management’s Werewolf Therapeutics HOWL Stock Holding History
Bought
Maintained
Sold
Other funds holding HOWL
RCM
VCM
MB
LCM
SFM
DF
SCM
VFT
Geode Capital Management's HOWL Position: Q1 2026 in Review
Geode Capital Management increased its Werewolf Therapeutics (HOWL) stake by 16% in Q1 2026, buying an estimated $36.7K and bringing the position to 389,487 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #3745.
Geode Capital Management first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.55M in Q4 2021. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.
- Geode Capital Management held 389,487 shares of Werewolf Therapeutics worth $324K as of Q1 2026.
- Geode Capital Management bought 53,601 Werewolf Therapeutics shares in Q1 2026, an estimated $36.7K.
- Werewolf Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3745 holding.
- Geode Capital Management first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
- Geode Capital Management's Werewolf Therapeutics position peaked at $2.55M in Q4 2021.
- 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.